EPA announces new non-animal chemical testing approaches, tying work to a 2035 goal for phasing out mammal testing

The Environmental Protection Agency said Thursday it has taken additional steps toward a federal goal of ending animal testing of chemicals on mammals by 2035, announcing two new methods aimed at evaluating chemical toxicity without using mammals. EPA officials described the announcement as part of a broader shift toward non-animal testing technologies and regulatory acceptance of those tools for safety assessment.

According to EPA, the newly announced methods are designed to help determine how chemicals may affect health by measuring toxicity using approaches that do not require mammal studies. The agency framed the move as a practical expansion of the available testing toolkit, intended to support how regulators evaluate chemicals and manage risk under existing federal authorities.

The EPA announcement also reiterated the agency’s long-term timeline, stating that the work is aligned with a phaseout target for all mammal testing by 2035. Under that framework, the agency has said it intends to increase the use of validated alternatives as they become available and scientifically reliable for regulatory decision-making.

Supporters of non-animal testing have argued that modern methods can reduce reliance on mammal studies while still supporting health and safety evaluation, and EPA’s announcement was presented as advancing that regulatory pathway. Critics, however, have previously raised concerns about coverage and how alternative methods translate across chemical classes and exposure scenarios, pointing to the importance of validation and data quality for public-health decisions.

In the near term, EPA’s decision is likely to affect how regulated parties develop toxicity data for chemical submissions and how the agency evaluates those data when making determinations about chemical safety. Even when alternative methods are available, agencies typically apply them in conjunction with established frameworks for evidence review, and the practical impact can depend on how those methods are accepted for specific regulatory purposes.

For the regulated community, the announcement can carry compliance implications, particularly for companies required to generate toxicity information for chemicals used in consumer products, industrial settings, and manufacturing. If alternative methods are used more widely, regulated entities may adjust testing plans and documentation practices to align with EPA expectations and evolving scientific validation standards.

The EPA announcement also raises questions about how the 2035 objective will be implemented over time, including the pace at which new alternatives are validated, the scope of chemicals and endpoints covered by the methods, and how the agency will manage any gaps where mammal testing remains necessary under current regulatory or scientific limitations. EPA did not indicate Thursday what specific endpoints or product categories will change immediately, but it said the new approaches represent continued progress toward the longer-term phaseout.

As EPA continues to expand non-mammal testing capacity, the next steps will likely include continued scientific review, method validation, and integration of the alternatives into regulatory processes, alongside ongoing coordination with stakeholders. The agency’s timeline and the practical adoption of the methods may become clearer as EPA details how they will be used for particular submission pathways and toxicity endpoints.